View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 19, 2020updated 02 Nov 2021 6:05am

Siemens Healthineers’ Covid-19 antibody test achieves CE mark

Germany-based company Siemens Healthineers has received CE mark for its SARS-CoV-2 IgG antibody test, enabling its use across Europe and other regions.

Germany-based firm Siemens Healthineers has received CE mark for its SARS-CoV-2 IgG antibody test, enabling its use across Europe and other regions.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The test has proven to measure neutralising antibodies, which are vital to fighting Covid-19 as they defend cells from viral infection.

The company has submitted an application to the US F ood and Drug Administration (F DA) for emergency use authorisation (EUA).

Once vaccines for Covid-19 become available, the fully automated antibody tests can detect whether the vaccination programmes are working or not.

Identifying the presence of these neutralising antibodies and evaluating the level required to protect against future encounters with the virus is essential to analyse a vaccine’s effectiveness, Siemens noted.

An enhanced version of an assay launched recently across the world. The test measures the amount of neutralising antibodies in a patient’s blood sample and delivers quantitative results.

Siemens -Healthineers-AG/”>Siemens Healthineers Laboratory Diagnostics president Deepak Nath said: “We targeted the spike protein for our antibody tests, anticipating antibodies to this protein would eventually prove to be neutralising.

“Adequate data is available now to confirm the spike protein antibodies are indeed neutralising, especially those against the spike receptor-binding domain.

“Healthcare providers can feel confident that our test will help them determine whether a patient’s immune system is producing the right antibodies to stop or prevent Covid-19 infection.”

The tests are available globally on the largest installed bases of automated immunoassay analysers.

Siemens Healthineers also has a diagnostic that can help in the prognosis, treatment, and follow-up of Covid-19 patients apart from the antibody, antigen, and molecular tests.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network